Auragen chooses SeqOne for genomic interpretation
Similar readings
-
Events News11 May 2023
SeqOne at ESHG 2023: A.I. for Diagnostics
We will be hosting a corporate satellite on Monday, June 12, 2023 – 14.00 – 15.30 BST : "Harnessing AI to improve diagnostic yield with [...]
-
News Press release
22 February 2023
SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors. SeqOne’s test simplifies the deployment of this test while [...]
-
News Platform features Press release Science
9 February 2023
SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
Montpellier, February 9th, 2023: SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving [...]
